This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Area

Beyonttra
®
▼(acoramidis)

Cardiovascular-related Hospitalisation (CVH)

Efficacy CVH

Efficacy: CVH

More Freedom: Beyonttra reduces the risk of CVH, enabling patients to manage their lives with more confidence.

Beyonttra continued to protect adults with ATTR-CM from time-to-first CV hospitalisations through Month 42. Participants who completed the 30-month ATTRibute-CM study were invited to participate in the Open Label Extension (OLE) study.

Efficacy CVH
Efficacy CVH
Beyonttra®▼ (acoramidis) - All-cause mortality in the OLE
Learn more about the All-cause mortality in the open-label extension of Beyonttra® (acoramidis).
PP-BEY-IE-0037-1, November 2025
Beyonttra®▼ (acoramidis) - Post-hoc Analysis of serum TTR
Learn more about the Efficacy: Post-hoc Analysis of serum transthyretin (TTR) of Beyonttra® (acoramidis).
PP-BEY-IE-0042-1, November 2025
Beyonttra®▼ (acoramidis) - Safety Profile
Learn more about the Safety Profile of Beyonttra® (acoramidis).
PP-BEY-IE-0033-1, November 2025

Abbreviations:

ARR
, absolute risk reduction;
CI
, confidence interval;
CVH,
 cardiovascular-related hospitalisation;
RRR
, relative risk reduction;
OLE
, open-label extension

 

PP-BEY-IE-0038-1   |   November 2025

 

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professional are asked to report any suspected adverse reactions.